3 Systematic review of treatment efficacy of PFPT 67 Improvement of pelvic floor symptoms Symptom improvement was investigated in 2 RCTs,51,52 4 prospective studies44,47,49,50 and the case study.35 One RCT51 found equal and significant improvement in urinary symptoms in the CP/CPSS group measured with the NIH-CPSI. Interstitial Cystitis Symptom Index/Interstitial Cystitis Problem (ICSI/ICPI) scores also showed improvement in urinary symptoms but only in the IC/PBS patient group. Another RCT52 was unable to demonstrate a decrease in urgency and frequency ratings and ICSI/ICPI scores after PFPT. In a prospective study49 in patients with CP/CPPS, NIHCPSI total scores significantly decreased with approximately 30% after treatment. The second prospective study44 in CP/CPPS patients showed significant symptom improvement in the subdomain NIH-CPSI-micturition. The third prospective study47 found significant improvement in the American Urological Association Symptom and Bother Score and VAS urgency and VAS voiding frequency scores in patients with CP/CPPS. Significant improvement in symptoms measured with ICSI/ICPI was seen in the fourth prospective study50 in patients with IC. At long-term followup, the improvement in ICPI and ICSI scores remained statistically significant. The case study35 found that overall 72% of patients reported marked (46%) or moderate (26%) improvement after PFPT. Urinary symptoms decreased significantly in patients reporting marked improvements. More than half of the patients treated with PFPT had a 25% or greater decrease in urinary symptom scores, as assessed by the PPSS. Quality of life Quality of life was measured in 3 RCTs,48,51,52 and 4 prospective studies44,45,49,50 and the case study.35 One RCT48 in patients with dyspareunia found significant improvement in QoL from pre-to post-treatment but not compared to controls measured with the Cervantes scale. Another RCT52 in IC/PBS patients found no significant improvement relative to controls in quality of life using the 12-item Short Form Survey (SF12). In the RCT51 with CP/CPPS and IC/PBS patients no differences were found between treatment groups in the QoL-domain of the SF-12, whereas a significant pre-post treatment improvement was found using both the SF-12 and NIH-CPSI, but in the CP/CPPS group only. One prospective study45 found a significant decrease in the perceived negative impact of PVD on QoL measured with a VAS-scale. Two prospective studies44,49 in men with CP/CPPS found a significant improvement in the NIH-CPSI subdomain QoL scores. Another prospective study50 in women with
RkJQdWJsaXNoZXIy MTk4NDMw